Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).

Zhu H, Liu Q, Xu H, Mo M, Wang Z, Lu K, Zhou J, Chen J, Zheng X, Ye J, Ge X, Luo H, Liu Q, Deng J, Ai D, Hao S, Zhang J, Tseng IH, Song S, Chen Y, Zhao K.

Open source

DOI
10.1186/s13014-022-02099-y
Published
2022-07-29
Container
Radiat Oncol
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s13014-022-02099-y,
  title = {Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).},
  author = {Zhu H and  Liu Q and  Xu H and  Mo M and  Wang Z and  Lu K and  Zhou J and  Chen J and  Zheng X and  Ye J and  Ge X and  Luo H and  Liu Q and  Deng J and  Ai D and  Hao S and  Zhang J and  Tseng IH and  Song S and  Chen Y and  Zhao K.},
  year = {2022},
  journal = {Radiat Oncol},
  doi = {10.1186/s13014-022-02099-y},
  url = {https://doi.org/10.1186/s13014-022-02099-y}
}

RIS

TY  - JOUR
TI  - Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).
AU  - Zhu H
AU  -  Liu Q
AU  -  Xu H
AU  -  Mo M
AU  -  Wang Z
AU  -  Lu K
AU  -  Zhou J
AU  -  Chen J
AU  -  Zheng X
AU  -  Ye J
AU  -  Ge X
AU  -  Luo H
AU  -  Liu Q
AU  -  Deng J
AU  -  Ai D
AU  -  Hao S
AU  -  Zhang J
AU  -  Tseng IH
AU  -  Song S
AU  -  Chen Y
AU  -  Zhao K.
PY  - 2022
JO  - Radiat Oncol
DO  - 10.1186/s13014-022-02099-y
UR  - https://doi.org/10.1186/s13014-022-02099-y
ER  - 

APA

H, Z., Q, L., H, X., M, M., Z, W., K, L., J, Z., J, C., X, Z., J, Y., X, G., H, L., Q, L., J, D., D, A., S, H., J, Z., IH, T., S, S., Y, C., & K., Z. (2022). Dose escalation based on <sup>18</sup>F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).. Radiat Oncol. https://doi.org/10.1186/s13014-022-02099-y

Source records